Literature DB >> 22644903

Treatment of perimenstrual migraine with triptans: an update.

Barbara Casolla1, Luana Lionetto, Serena Candela, Lidia D'Alonzo, Andrea Negro, Maurizio Simmaco, Paolo Martelletti.   

Abstract

Pure menstrual migraine (PMM) and menstrually related migraine (MRM) are difficult challenges in migraine management. Triptans are a class of highly selective serotonin receptor agonists, which interfere with the pathogenesis of migraine and are effective in relieving the associated neurovegetative symptoms. In recent years triptans have been extensively proposed for the treatment of severe, disabling, and recurrent perimenstrual migraine attacks. This review summarizes the different levels of recommendations for the use of triptans in the treatment of perimenstrual migraine. This review is also intended to offer an updated reasonable guide to physicians treating perimenstrual migraine in daily practice.

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22644903     DOI： 10.1007/s11916-012-0280-0

Source DB:  PubMed          Journal:  Curr Pain Headache Rep        ISSN： 1534-3081


  50 in total

1.  Menstrual migraine: update on pathophysiology and approach to therapy and management.

Authors:  Anne H Calhoun
Journal:  Curr Treat Options Neurol       Date:  2012-02       Impact factor: 3.598

2.  Guidance for the preparation of neurological management guidelines by EFNS scientific task forces--revised recommendations 2004.

Authors:  M Brainin; M Barnes; J-C Baron; N E Gilhus; R Hughes; K Selmaj; G Waldemar
Journal:  Eur J Neurol       Date:  2004-09       Impact factor: 6.089

3.  Efficacy and tolerability of almotriptan in menstrual migraine: a comment.

Authors:  Luana Lionetto; Martina Fiorillo; Paolo Martelletti
Journal:  Expert Opin Pharmacother       Date:  2011-10       Impact factor: 3.889

4.  Rizatriptan in the treatment of menstrual migraine.

Authors:  S D Silberstein; H Massiou; C Le Jeunne; L Johnson-Pratt; K A McCarroll; C R Lines
Journal:  Obstet Gynecol       Date:  2000-08       Impact factor: 7.661

5.  Pain-free efficacy after treatment with sumatriptan in the mild pain phase of menstrually associated migraine.

Authors:  Robert Nett; Steve Landy; Steve Shackelford; Mary S Richardson; Michael Ames; Michelle Lener
Journal:  Obstet Gynecol       Date:  2003-10       Impact factor: 7.661

6.  Oral zolmitriptan in the short-term prevention of menstrual migraine: a randomized, placebo-controlled study.

Authors:  Michael M Tuchman; Angela Hee; Ugochi Emeribe; Stephen Silberstein
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

7.  A randomized trial of frovatriptan for the intermittent prevention of menstrual migraine.

Authors:  Stephen D Silberstein; Arthur H Elkind; Curtis Schreiber; Charlotte Keywood
Journal:  Neurology       Date:  2004-07-27       Impact factor: 9.910

8.  EFNS guideline on the drug treatment of migraine--revised report of an EFNS task force.

Authors:  S Evers; J Afra; A Frese; P J Goadsby; M Linde; A May; P S Sándor
Journal:  Eur J Neurol       Date:  2009-09       Impact factor: 6.089

9.  Acute migraine therapy: new drugs and new approaches.

Authors:  Teshamae S Monteith; Peter J Goadsby
Journal:  Curr Treat Options Neurol       Date:  2011-02       Impact factor: 3.598

10.  Frovatriptan versus almotriptan for acute treatment of menstrual migraine: analysis of a double-blind, randomized, cross-over, multicenter, Italian, comparative study.

Authors:  Marco Bartolini; Maria Adelaide Giamberardino; Carlo Lisotto; Paolo Martelletti; Davide Moscato; Biagio Panascia; Lidia Savi; Luigi Alberto Pini; Grazia Sances; Patrizia Santoro; Giorgio Zanchin; Stefano Omboni; Michel D Ferrari; Brigida Fierro; Filippo Brighina
Journal:  J Headache Pain       Date:  2012-05-17       Impact factor: 7.277
View more
  5 in total

1.  Frovatriptan and rizatriptan economic EVAluation: the FREEVA study.

Authors:  Carlo Lisotto; Mario Guidotti; Dario Zava; Lidia Savi
Journal:  J Headache Pain       Date:  2013-12-11       Impact factor: 7.277

2.  Temporal relations in hormone-withdrawal migraines and impact on prevention- a diary-based pilot study in combined hormonal contraceptive users.

Authors:  Gabriele S Merki-Feld; Gina Epple; Nina Caveng; Bruno Imthurn; Burkhardt Seifert; Peter Sandor; Andreas R Gantenbein
Journal:  J Headache Pain       Date:  2017-08-25       Impact factor: 7.277

3.  Treatment of menstrual migraine; multidisciplinary or mono-disciplinary approach.

Authors:  Hester Witteveen; Peter van den Berg; Guus Vermeulen
Journal:  J Headache Pain       Date:  2017-04-17       Impact factor: 7.277

Review 4.  Triptans in prevention of menstrual migraine: a systematic review with meta-analysis.

Authors:  Yong Hu; Xiaofei Guan; Lin Fan; Lingjing Jin
Journal:  J Headache Pain       Date:  2013-01-30       Impact factor: 7.277

5.  Non-invasive Vagus Nerve Stimulation (nVNS) as mini-prophylaxis for menstrual/menstrually related migraine: an open-label study.

Authors:  Licia Grazzi; Gabriella Egeo; Anne H Calhoun; Candace K McClure; Eric Liebler; Piero Barbanti
Journal:  J Headache Pain       Date:  2016-10-03       Impact factor: 7.277
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.